Net clinical benefit of extended dual pathway inhibition in chronic coronary syndrome as classified by the 2024 ESC criteria: a COMPASS substudy.

Eur Heart J Cardiovasc Pharmacother · 2026 · PMC13185743 · PMID 41614385

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, the P -value for interaction did not reach statistical significance, and drawing further conclusions from these findings appears speculative.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.